Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13385745 | 0.83 | GAA (0.66) | GAASMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL25202069 | 0.77 | GAA (0.56) | GAASMN1; SMN2GRM5RAB9ANPC1 | |
| SCHEMBL5359661 | 0.77 | GAA (0.66) | GAASMN1; SMN2RAB9ANPC1HDAC1 | |
| SCHEMBL16345114 | 0.75 | GAA (0.59) | GAASMN1; SMN2RAB9ANPC1F2 | |
| SCHEMBL13060617 | 0.75 | GAA (0.66) | GAASMN1; SMN2RAB9ANPC1F2 | |
| SCHEMBL29995352 | 0.73 | SMN1; SMN2 (0.61) | GAASMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL23388826 | 0.73 | SMN1; SMN2 (0.61) | GAASMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL7129699 | 0.73 | ALDH1A1 (0.57) | GAAGRM5HDAC1HDAC2KAT6A | |
| SCHEMBL3222288 | 0.72 | GAA (0.64) | GAASMN1; SMN2RAB9ANPC1PKM | |
| SCHEMBL25233274 | 0.72 | NPC1 (0.66) | GAASMN1; SMN2RAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| US-20110280803-A1 | RADIOIODINATION METHOD | GE HEALTHCARE UK LIMITED (GB) | 2011-11-17 | — | — | US | disclosed |
| EP-2382185-A1 | RADIOIODINATION METHOD | GE Healthcare Limited (GB) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010086398-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086398-A1 | RADIOIODINATION METHOD | GE HEALTHCARE LIMITED (GB) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110280803-A1 | RADIOIODINATION METHOD | TPO, SSTR5, DAO | GAA 3317/4885SMN1; SMN2 4880/4885GRM5 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.